Who is sponsoring NCT01410799?

NCT01410799 is sponsored by University of Pennsylvania.

What condition does NCT01410799 study?

NCT01410799 studies Hormone Deficiency, Aging.

What drugs are being tested in NCT01410799?

Interventions: Growth Hormone Releasing Hormone (GHRH ).

What is the status of NCT01410799?

NCT01410799 is currently TERMINATED.

Last reviewed 2019-05-23 · How we verify

Three Month Treatment of GHRH (Growth Hormone Releasing Hormone) in the Elderly

NCT01410799 Phase 2 TERMINATED Results posted

The purpose of the study is to evaluate the effect of a naturally occurring hormone, called Growth Hormone Releasing Hormone (GHRH) on the muscle, bone, and fat tissues of the body. GHRH stimulates the production of growth hormone (GH), which regulates the build up of many tissues in the body, including muscles and bones. Many elderly people have low levels of GH. The overall goal of this research is to determine the efficacy of GHRH to raise levels of GH and improve these body tissues. Healthy men and women age 65 and older will receive GHRH in four doses nightly for 12 weeks and assessed for changes in muscle strength, body mass, physical performance, and how the body uses sugar.

Details

Lead sponsor	University of Pennsylvania
Phase	Phase 2
Status	TERMINATED
Enrolment	13
Start date	2011-05
Completion	2011-08

Conditions

Hormone Deficiency
Aging

Interventions

Growth Hormone Releasing Hormone (GHRH )

Primary outcomes

Muscle Strength — 12 weeks
Pre-drug and post-drug 1 RM (Repetition Maximum) testing

Countries

United States